# A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

> **NCT07060989** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Nutshell Therapeutics (Shanghai) Co., LTD.** · enrollment: 220 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** NTS071

## Key facts

- **NCT ID:** NCT07060989
- **Lead sponsor:** Nutshell Therapeutics (Shanghai) Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07060989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07060989, "A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07060989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*